Melanie Tepus1, Tung On Yau1. 1. John van Geest Cancer Research Centre, School of Science and Technology, Nottingham Trent University, Nottingham, United Kingdom.
Abstract
BACKGROUND: Colorectal cancer (CRC) follows a protracted stepwise progression, from benign adenomas to malignant adenocarcinomas. If detected early, 90% of deaths are preventable. However, CRC is asymptomatic in its early-stage and arises sporadically within the population. Therefore, CRC screening is a public health priority. SUMMARY: Faecal immunochemical test (FIT) is gradually replacing guaiac faecal occult blood test and is now the most commonly used screening tool for CRC screening program globally. However, FIT is still limited by the haemoglobin degradation and the intermittent bleeding patterns, so that one in four CRC cases are still diagnosed in a late stage, leading to poor prognosis. A multi-target stool DNA test (Cologuard, a combination of NDRG4 and BMP3 DNA methylation, KRAS mutations, and haemoglobin) and a plasma SEPT9 DNA methylation test (Epi proColon) are non-invasive tools also approved by the US FDA, but those screening approaches are not cost-effective, and the detection accuracies remain unsatisfactory. In addition to the approved tests, faecal-/blood-based microRNA and CRC-related gut microbiome screening markers are under development, with work ongoing to find the best combination of molecular biomarkers which maximise the screening sensitivity and specificity. KEY MESSAGE: Maximising the detection accuracy with a cost-effective approach for non-invasive CRC screening is urgently needed to further reduce the incidence of CRC and associated mortality rates.
BACKGROUND: Colorectal cancer (CRC) follows a protracted stepwise progression, from benign adenomas to malignant adenocarcinomas. If detected early, 90% of deaths are preventable. However, CRC is asymptomatic in its early-stage and arises sporadically within the population. Therefore, CRC screening is a public health priority. SUMMARY: Faecal immunochemical test (FIT) is gradually replacing guaiac faecal occult blood test and is now the most commonly used screening tool for CRC screening program globally. However, FIT is still limited by the haemoglobin degradation and the intermittent bleeding patterns, so that one in four CRC cases are still diagnosed in a late stage, leading to poor prognosis. A multi-target stool DNA test (Cologuard, a combination of NDRG4 and BMP3 DNA methylation, KRAS mutations, and haemoglobin) and a plasma SEPT9 DNA methylation test (Epi proColon) are non-invasive tools also approved by the US FDA, but those screening approaches are not cost-effective, and the detection accuracies remain unsatisfactory. In addition to the approved tests, faecal-/blood-based microRNA and CRC-related gut microbiome screening markers are under development, with work ongoing to find the best combination of molecular biomarkers which maximise the screening sensitivity and specificity. KEY MESSAGE: Maximising the detection accuracy with a cost-effective approach for non-invasive CRC screening is urgently needed to further reduce the incidence of CRC and associated mortality rates.
Authors: Eline H Schreuders; Arlinda Ruco; Linda Rabeneck; Robert E Schoen; Joseph J Y Sung; Graeme P Young; Ernst J Kuipers Journal: Gut Date: 2015-06-03 Impact factor: 23.059
Authors: Janneke A Wilschut; Lieke Hol; Evelien Dekker; Jan B Jansen; Monique E Van Leerdam; Iris Lansdorp-Vogelaar; Ernst J Kuipers; J Dik F Habbema; Marjolein Van Ballegooijen Journal: Gastroenterology Date: 2011-07-22 Impact factor: 22.682
Authors: Patrick S Mitchell; Rachael K Parkin; Evan M Kroh; Brian R Fritz; Stacia K Wyman; Era L Pogosova-Agadjanyan; Amelia Peterson; Jennifer Noteboom; Kathy C O'Briant; April Allen; Daniel W Lin; Nicole Urban; Charles W Drescher; Beatrice S Knudsen; Derek L Stirewalt; Robert Gentleman; Robert L Vessella; Peter S Nelson; Daniel B Martin; Muneesh Tewari Journal: Proc Natl Acad Sci U S A Date: 2008-07-28 Impact factor: 11.205
Authors: Veerle Melotte; Marjolein H F M Lentjes; Sandra M van den Bosch; Debby M E I Hellebrekers; Joep P J de Hoon; Kim A D Wouters; Kathleen L J Daenen; Iris E J M Partouns-Hendriks; Filip Stessels; Joost Louwagie; Kim M Smits; Matty P Weijenberg; Silvia Sanduleanu; Carolina A J Khalid-de Bakker; Frank A Oort; Gerrit A Meijer; Daisy M A E Jonkers; James G Herman; Adriaan P de Bruïne; Manon van Engeland Journal: J Natl Cancer Inst Date: 2009-06-17 Impact factor: 13.506
Authors: Chung Wah Wu; Siew Chien Ng; Yujuan Dong; Linwei Tian; Simon Siu Man Ng; Wing Wa Leung; Wai Tak Law; Tung On Yau; Francis Ka Leung Chan; Joseph Jao Yiu Sung; Jun Yu Journal: Clin Cancer Res Date: 2014-04-01 Impact factor: 12.531
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702